Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Retinal Vein Occlusions
Interventions: Not listed
Lead sponsor: Barnes Retina Institute; Other
Eligibility: 21 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes Mellitus, Diabetic Retinopathy
Interventions: EyePromise DVS, EyePromise DVS plus EyePromise EZTears; Dietary Supplement
Lead sponsor: ZeaVision, LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Wet Macular Degeneration
Interventions: Faricimab, Aflibercept, Sham Procedure; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 658 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 41
States / cities: Phoenix, Arizona • Mountain View, California • Sacramento, California + 36 more

Conditions: Geographic Atrophy, Age-related Macular Degeneration
Interventions: LFG316, Sham, LFG316 Lower dose; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 55 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 19
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 15 more

Conditions: Active Noninfectious Uveitis Affecting the Posterior Segment
Interventions: REGN7041; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Sacramento, California • Oak Park, Illinois • Nashville, Tennessee + 2 more

Conditions: Diabetic Retinopathy
Interventions: doxycycline monohydrate, placebo; Drug
Lead sponsor: Thomas Gardner; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Leber Congenital Amaurosis
Interventions: rAAV2-CB-hRPE65; Biological
Lead sponsor: Beacon Therapeutics; Industry
Eligibility: 6 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 2
States / cities: Worcester, Massachusetts • Portland, Oregon

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Home vision monitoring using myVisionTrack®; Device
Lead sponsor: Vital Art and Science Incorporated; Industry
Eligibility: 40 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Cognitive Impairment, Progressive, Cerebral Small Vessel Diseases
Interventions: High-Speed Circuit Resistance Training, Lecture on Diet, Exercise and Cognition; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 65 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Coral Gables, Florida

Conditions: Pigmentary Maculopathy, Pigmentary Retinopathy, Interstitial Cystitis
Interventions: Not listed
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Titusville, New Jersey

Conditions: Age-related Macular Degeneration (AMD)
Interventions: Nidek MP-3; Device
Lead sponsor: Doheny Image Reading Center; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Retinopathy of Prematurity
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 32 Weeks to 40 Weeks
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 11
States / cities: Louisville, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 8 more

Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions: nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX), Theratears tear drop, (Akron, Ann 111 Arbor, MI), patching; Drug · Other
Lead sponsor: The New York Eye & Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Retinal Disease
Interventions: IRX-101, Providone-Iodine; Drug
Lead sponsor: iRenix Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Epiretinal Membrane
Interventions: 27-gauge vitrectomy wound construction; Device
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Ranibizumab, Triamcinolone Acetonide, Sham injection, Focal/grid laser; Drug · Behavioral · Procedure
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 56
States / cities: Artesia, California • Beverly Hills, California • Irvine, California + 46 more

Conditions: Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis, Huntington Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Neuro-Degenerative Disease, Normal Cognition
Interventions: Retinal and Choroidal Imaging; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Age-related Macular Degeneration, Coronary Artery Disease, Cardiovascular Diseases
Interventions: Blood draw; Genetic
Lead sponsor: The New York Eye & Ear Infirmary; Other
Eligibility: 50 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Microvascular Disease, Retinal Disease
Interventions: XyCAM CRE Imaging; Device
Lead sponsor: Stuart Terry Eye Associates; Other
Eligibility: 21 Years to 100 Years
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Age Related Macular Degeneration, Geographic Atrophy
Interventions: Not listed
Lead sponsor: Carl Zeiss Meditec, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: Oakland, California • Jackson, Michigan

Conditions: Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration
Interventions: Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system, MB-102 and commercially available optical angiography imaging system; Combination Product
Lead sponsor: MediBeacon; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Central Serous Chorioretinopathy
Interventions: rhuFab V2 [ranibizumab] ( Lucentis ); Drug
Lead sponsor: Vitreous -Retina- Macula Consultants of New York; Other
Eligibility: Not listed
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: X-Linked Retinitis Pigmentosa
Interventions: rAAV2tYF-GRK1-RPGR; Biological
Lead sponsor: Beacon Therapeutics; Industry
Eligibility: 8 Years to 50 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 6
States / cities: Jacksonville, Florida • Boston, Massachusetts • Cincinnati, Ohio + 3 more

Conditions: Diabetic Macular Edema
Interventions: Macugen® pegaptanib sodium; Drug
Lead sponsor: Valley Retina Institute; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: McAllen, Texas

Search by objective public record fields.

Anatomic Outcomes Following Ozurdex Injections

Combined Effects of Diabetes Self-Management Education and Nutritional Supplementation on Visual Function and Retinopathy

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)

A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants

Evaluation of Doxycycline Verses Placebo for the Treatment of Severe Nonproliferative or Mild or Moderate Proliferative Diabetic Retinopathy

Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis

Diabetic Retinopathy And the Myvisiontrack® (DRAMA) Study

Circuit Training and Retina

A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy

Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device

Telemedicine Approaches to Evaluating Acute-phase ROP

Post Intravitreal Injection Topical NSAID vs. Patching

Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections

27-gauge Vitrectomy Wound Integrity: a Prospective, Randomized Trial Comparing Angled Versus Straight Entry

Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy

Retinal Imaging in Neurodegenerative Disease

Age-related Macular Degeneration (AMD) and Cardiovascular Disease

Collecting Data on Retinal Blood Blood Flow and Blood Vessel Shape/Appearance Using an Investigational Device, XyCAM CRE, and to Then Compare Those Images With Images Collected From a Patient's Routine Clinical Examination.

Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE)

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy

A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)

Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study